Quantcast

Prostate Cancer Hits African-American Men Especially Hard

New America Media | 10/14/2012, 11:08 a.m.

MIAMI -- Marc Henderson, a 63-year-old African-American airport administrator here, isn't afraid to ask his physician to do a blood test for Prostate Specific Antigen (PSA), a screening test for prostate cancer.

"I'd rather know early on so that it can be treated, rather than sit around in denial until it's too late," he said. "If it's going to help catch something, I have no problems with it."

Henderson's views aren't unusual. For years, doctors have routinely ordered the PSA on men older than 50, along with tests for cholesterol and blood sugar. Just as the goal of screening mammograms is to prevent deaths from breast cancer, the goal of routine PSA testing is to catch prostate cancer early, when it's easier to treat and more likely to be cured.

Prostate cancer is the second leading cause of cancer death among men in the United States, and routine PSA tests have led to the diagnosis of early prostate cancer in millions of men with no symptoms of the disease. Overall, 16 out of 100 men will be diagnosed with prostate cancer during their lifetime, and three out of 100 will die of the disease.

Prostate cancer hits black men especially hard. One out of every five black men will be diagnosed with the disease during his lifetime, and five out of 100 will die from it. Black men are more likely to be diagnosed with prostate cancer that is more aggressive and more advanced than are men of other ethnicities. They are also more likely to develop the disease at a younger age than other men.

Unfortunately, the PSA isn't a great test. It's often abnormal in men who don't have cancer (and sometimes, it's normal in men who do have cancer). Widespread testing has led to millions of men without prostate cancer undergoing biopsies, in which a needle is used to take a small piece of the prostate to examine under the microscope. Also, prostate cancer is extremely common, and most early cases don't spread to other organs. Those that do spread often take many years to progress to the point where they are fatal. Most men with prostate cancer die of other diseases. Because of early detection, many men undergo aggressive treatment for a cancer that, left alone, would not kill them.

Because of these drawbacks, the United States Preventive Services Task Force (USPSTF), a prominent panel of doctors and health experts, recommended earlier this year that men not undergo routine screening. After reviewing several large studies of PSA testing, the panel concluded that the risks of testing - specifically, complications of biopsies and of treatment, such as infections, bleeding, urinary and sexual problems - outweigh the benefit of lives saved as a result of the test. The USPSTF reported that routine PSA testing saves one man out of 1,000 - at most - from dying of prostate cancer.

Meanwhile, out of 1,000 men who are screened, 30 to 40 will develop erectile dysfunction or problems controlling their urination, two will have a heart attack or stroke, and one will develop a potentially life-threatening blood clot as a result of treatment for prostate cancer. In all, the USPSTF reported, one out of 3,000 men screened for prostate cancer will die due to complications from surgical treatment.